Related Experiment Video
Updated: Feb 12, 2026

Double-barreled and Concentric Microelectrodes for Measurement of Extracellular Ion Signals in Brain Tissue
Published on: September 5, 2015
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Yanxin Lu1, Yang Liu2, Ying Pang3
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Basic Medical Science Department, Zunyi Medical College-Zhuhai Campus, Zhuhai, Guangdong 519041, PR China.
Abstract:
DNA repair pathways are evolutionarily conserved molecular mechanisms that maintain the integrity of genomic DNA. In cancer therapies, the integrity and activity of DNA repair pathways predict therapy resistance and disease outcome. Members of the poly (ADP-ribose) polymerase (PARP) family initiate and organize the biologic process of DNA repair, which counteracts many types of chemotherapies. Since the first development in approximately 3 decades ago, PARP inhibitors have greatly changed the concept of cancer therapy, leading to encouraging improvements in tumor suppression and disease outcomes. Here we summaries both pre-clinical and clinical findings of PARP inhibitors applications, particularly for combination therapies.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors are crucial in cancer therapy, improving outcomes by targeting DNA repair mechanisms. This review summarizes their use, especially in combination therapies, for enhanced tumor suppression.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- DNA repair pathways are essential for maintaining genomic integrity.
- The activity of DNA repair pathways influences cancer therapy resistance and patient outcomes.
- Poly (ADP-ribose) polymerase (PARP) enzymes play a key role in DNA repair and can counteract chemotherapy.
Purpose of the Study:
- To review the pre-clinical and clinical findings on the application of PARP inhibitors in cancer therapy.
- To highlight the potential of PARP inhibitors, particularly in combination therapies.
Main Methods:
- Literature review of pre-clinical studies on PARP inhibitors.
- Analysis of clinical trial data for PARP inhibitor efficacy.
- Examination of combination therapy strategies involving PARP inhibitors.
Main Results:
- PARP inhibitors have significantly advanced cancer treatment concepts over the past three decades.
- These inhibitors show encouraging improvements in tumor suppression and disease outcomes.
- Their application, especially in combination therapies, is a key area of research.
Conclusions:
- PARP inhibitors represent a significant therapeutic advancement in oncology.
- Combination therapies involving PARP inhibitors hold great promise for improving cancer treatment efficacy.
- Further research into PARP inhibitor applications is warranted to optimize patient outcomes.
Related Concept Videos
Sign Convention
The normal force acts perpendicular to the beam's cross-section and can...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Multi-pass Transmembrane Proteins and β-barrels
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
Enolate Mechanism Conventions
Fixing Double-strand Breaks
Fixing Double-strand Breaks

